Jade Biosciences (JBIO) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.76
- Estimate
- -$0.54
- Surprise
- -40.3%
- Score today
- 4.8/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Jade Biosciences (JBIO) reported a wider loss than forecast — adjusted EPS of -$0.76 against the -$0.54 estimate (a 40.3% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates JBIO Sell at 4.8/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -40.3% surprise compares with a -27.6% four-quarter average. Next scheduled report: 2026-11-12.
What argues against it
- Concentration risk — Pipeline: JADE101
- DATA_ISSUE: analyst_target_implausible (raw $50.12 vs price $14.74 — ratio 3.4×). Rejected, falling back to technical TP.
- Quality below floor (2.5 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $14.74
- Price target
- $15.13
- Stop
- $13.71
- Upside to target
- +2.6%
Model outputs from TrendMatrix’s engine as of 2026-10-27 — shown for context, not personalized investment advice.
JBIO at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $922.2M
- P/E (fwd)
- -5.4
- 52-week range
- $8.36–$28.00
- Off 52-week high
- 47.4%
- RSI (14)
- 60
- Volume vs avg
- 0.71×
- Score today
- 4.8/10